olivLaw · US equity research
OmniAb, Inc. OABI
Services-Commercial Physical & Biological Research · SIC 8731 · Vertical: Services-Commercial Physical & Biological Research (SIC 8731)
OmniAb licenses antibody discovery technology to pharmaceutical, biotech and academic customers, earning revenue from access fees, services, milestones and royalties. The company raised its 2026 outlook in August 2026, amid business momentum and 27.8 mn USD of revenue in the first half. For readers, the outcome depends largely on partner programs that OmniAb does not control.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, OmniAb, Inc. (OABI) stock was 5.18 USD (+0.58% on the day), with market capitalisation 755.6 m USD, dividend yield 48.26%, beta 1.07, 52-week range 1.36–5.28 USD. Latest reported quarter (Q3 2026): revenue of 4.0 m USD (+78.3% YoY), net income of -15.7 m USD, diluted EPS -0.12 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 60.1
- strong (55–70)
- Bollinger (20, 2)
- 4.41 – 5.33
- in the upper half of the band · %B 0.84 · band width 18.7%
- SMA 50 / 200
- 4.69 / 2.75
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 0.16 / 0.14
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +5.3% | −1.1% | +6.4 pp | — |
| 3 months | +155.2% | −0.5% | +155.6 pp | — |
| 6 months | +262.2% | +4.4% | +257.8 pp | — |
| Year to date | +180.0% | +12.3% | +167.7 pp | — |
| 1 year | +250.0% | +13.5% | +236.5 pp | +10.9% |
| 3 years | +10.2% | +76.4% | −66.2 pp | −23.9% |
| 5 years | −48.0% | +63.7% | −111.7 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q3 2026 · 30 Sept 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 10.8 m | 4.2 m | 3.9 m | 2.2 m | 8.4 m | 14.4 m | 13.4 m | 4.0 m |
| Research & development | 13.3 m | 12.6 m | 10.9 m | 10.4 m | 13.9 m | 9.6 m | 9.6 m | 9.6 m |
| Operating income | -15.9 m | -18.8 m | -16.2 m | -18.1 m | -15.8 m | -7.8 m | -6.6 m | -16.4 m |
| Depreciation & amortisation | 7.6 m | 4.7 m | 4.6 m ≈ | 4.7 m ≈ | 7.7 m | — | — | — |
| Pre-tax income | -15.2 m | -18.3 m | -15.8 m | -17.7 m | -14.5 m | -7.3 m | -6.2 m | -15.9 m |
| Income tax | -2.2 m | -106.0 k | 119.0 k | -1.2 m | -367.0 k | 442.0 k | -353.0 k | -127.0 k |
| Net income | -13.1 m | -18.2 m | -15.9 m | -16.5 m | -14.2 m | -7.7 m | -5.9 m | -15.7 m |
| Diluted EPS | -0.12 ≈ | -0.17 | -0.15 | -0.14 | -0.11 ≈ | -0.06 | -0.05 | -0.12 |
| Operating cash flow | -3.9 m | -15.9 m | -5.1 m ≈ | -9.8 m ≈ | -5.7 m | -4.9 m | 2.7 m ≈ | 10.6 m ≈ |
| Capex | 46.0 k | 209.0 k | 165.0 k ≈ | 182.0 k ≈ | 9.0 k | 167.0 k | 110.0 k ≈ | 0 ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2007 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | unavailable | 34.7 m | 59.1 m | 34.2 m | 26.4 m | 18.7 m |
| Revenue YoY | unavailable | unavailable | +70.0% | −42.2% | −22.8% | −29.3% |
| Net income | unavailable | -27.0 m | -22.3 m | -50.6 m | -62.0 m | -64.8 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | -0.33 | -0.26 | -0.51 | -0.61 | -0.57 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | unavailable | -77.8% | -37.8% | -148.2% | -235.1% | -347.0% |
| Free cash flow | unavailable | -9.7 m | -20.8 m | 703.0 k | -41.5 m | -37.0 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 25.5 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 267.0 m USD
- Total assets
- 300.9 m USD
- Debt / equity
- unavailable
- Current ratio
- 4.02x
- ROE
- -23.4%
- ROA
- -20.7%
- FCF margin
- -198.3%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2007 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | — | 34.7 m | 59.1 m | 34.2 m | 26.4 m | 18.7 m | SEC (XBRL)· 04 Mar 2026verified |
| Research & development | — | 39.2 m | 48.4 m | 56.5 m | 55.1 m | 47.8 m | SEC (XBRL)· 04 Mar 2026verified |
| Operating income | — | -35.6 m | -26.6 m | -69.4 m | -74.5 m | -69.0 m | SEC (XBRL)· 04 Mar 2026verified |
| Depreciation & amortisation | — | 16.3 m | 18.2 m | 19.5 m | 23.6 m | 21.8 m | SEC (XBRL)· 04 Mar 2026verified |
| EBITDA | — | -19.4 m ≈ | -8.4 m ≈ | -49.9 m ≈ | -50.9 m ≈ | -47.2 m ≈ | SEC (XBRL)· 04 Mar 2026derived |
| Interest expense | — | 7.0 k | 0 | — | — | — | SEC (XBRL)· 30 Mar 2023verified |
| Pre-tax income | — | -34.4 m | -26.1 m | -64.4 m | -71.4 m | -66.3 m | SEC (XBRL)· 04 Mar 2026verified |
| Income tax | — | -7.3 m | -3.7 m | -13.7 m | -9.4 m | -1.5 m | SEC (XBRL)· 04 Mar 2026verified |
| Net income | — | -27.0 m | -22.3 m | -50.6 m | -62.0 m | -64.8 m | SEC (XBRL)· 04 Mar 2026verified |
| Diluted EPS | — | -0.33 | -0.26 | -0.51 | -0.61 | -0.57 | SEC (XBRL)· 04 Mar 2026verified |
| Weighted average diluted shares | — | 82.6 m | 85.3 m | 99.7 m | 102.4 m | 113.6 m | SEC (XBRL)· 04 Mar 2026verified |
| Dividend per share | 2.50 | — | — | — | — | — | SEC (XBRL)· 30 Mar 2023verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2007 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | — | 0 | 33.4 m | 16.4 m | 27.6 m | 25.5 m | SEC (XBRL)· 04 Mar 2026verified |
| Receivables | — | 21.1 m | 30.3 m | 3.8 m | 5.3 m | 7.4 m | SEC (XBRL)· 04 Mar 2026verified |
| Inventories | — | — | — | — | 48.0 k | 823.0 k | SEC (XBRL)· 04 Mar 2026verified |
| Current assets | — | 22.5 m | 125.0 m | 94.9 m | 68.1 m | 65.3 m | SEC (XBRL)· 04 Mar 2026verified |
| Property, plant & equipment, net | — | 6.8 m | 20.0 m | 18.2 m | 15.5 m | 9.4 m | SEC (XBRL)· 04 Mar 2026verified |
| Goodwill | — | 84.0 m | 84.0 m | 84.0 m | 84.0 m | 84.0 m | SEC (XBRL)· 04 Mar 2026verified |
| Intangibles (excl. goodwill) | — | 176.3 m | 167.2 m | 155.5 m | 138.1 m | 125.1 m | SEC (XBRL)· 04 Mar 2026verified |
| Total assets | — | 304.5 m | 421.2 m | 375.2 m | 325.6 m | 300.9 m | SEC (XBRL)· 04 Mar 2026verified |
| Accounts payable | — | 2.9 m | 3.0 m | 4.4 m | 2.3 m | 1.9 m | SEC (XBRL)· 04 Mar 2026verified |
| Current liabilities | — | 20.6 m | 26.0 m | 23.1 m | 15.1 m | 16.3 m | SEC (XBRL)· 04 Mar 2026verified |
| Total liabilities | — | 70.2 m | 79.8 m | 60.6 m | 37.9 m | 33.9 m | SEC (XBRL)· 04 Mar 2026verified |
| Equity | — | 234.3 m † | 341.4 m † | 314.6 m † | 287.6 m † | 267.0 m † | SEC (XBRL)· 04 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2007 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | — | -5.7 m | -3.6 m | 2.3 m | -39.7 m | -36.5 m | SEC (XBRL)· 04 Mar 2026verified |
| Capex | — | 4.1 m | 17.2 m | 1.6 m | 1.9 m | 565.0 k | SEC (XBRL)· 04 Mar 2026verified |
| Free cash flow | — | -9.7 m ≈ | -20.8 m ≈ | 703.0 k ≈ | -41.5 m ≈ | -37.0 m ≈ | SEC (XBRL)· 04 Mar 2026derived |
| Investing cash flow | — | -4.0 m | -73.3 m | -18.4 m | 37.9 m | 6.5 m | SEC (XBRL)· 04 Mar 2026verified |
| Financing cash flow | — | 9.7 m | 110.7 m | -892.0 k | 13.0 m | 27.9 m | SEC (XBRL)· 04 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 4 of at least 6
- score weight coverage: 27.1% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 755.6 m USD
Key indicators
Coverage and freshness
Score by group
27% · Insufficient data
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 32.85 – 44.18 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · the reported interest expense is far older than the latest period (the filer changed its XBRL tag): a stale figure is not used
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)32.85 – 44.18 (Mid 37.68)
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 4 of at least 6; score weight coverage: 27.1% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -108.1% | 45 (vs peers) | 23% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | -31.9% | 0 (on a fixed band) | 31% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 4.2x | 100 (on a fixed band) | 15% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | 0.3% | 4 (on a fixed band) | 31% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth· partial0/100 · 1/2 factors with a value
- Quality· partial45/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial4/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
OMNIAB, INC. (OABI). Latest full fiscal year: 2025; data up to 2026-09-30.
Figures computed from the financial statements: revenue 18.7 m USD in 2025; YoY growth -29.3%; net margin -108.1%; ROE -16.5%.
The estimated value range is 32.85–44.18 USD per share (median of 1 methods, agreement: single method); assumptions are illustrative. Against the central value of 37.68 USD, the price of 5.18 USD leaves a potential of 627.5% (value / price − 1) and a margin of safety of 86.3% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (indicators available: 4 of at least 6; score weight coverage: 27.1% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 4.2x
- The price is below the estimated value range
What contradicts it
- Revenue CAGR 3Y: -31.9%
- FCF yield: 0.3%
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Services-Commercial Physical & Biological Research (SIC 8731) · same industry (4-digit SIC) · compared with 11 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| IQVIqvia Holdings Inc. | 43.5 bn | 32.0 | 21.7% | 8.1% | +5.9% | +15% / +23% |
| INCYIncyte Corporation | 25.0 bn | 65.2 | 7.8% | 6.7% | +21.2% | +18% / +126% |
| MEDPMedpace Holdings, Inc. | 18.4 bn | 36.4 | 117.9% | 18.2% | +20.0% | +11% / +143% |
| CRLCharles River Laboratories International, Inc. | 15.6 bn | 385.5 | 1.2% | 1.0% | −0.9% | +83% / +66% |
| ICLRICON plc | 15.6 bn | 70.0 | 2.5% | 2.8% | +0.8% | +10% / −24% |
| ABSIAbsci Corp | 1.8 bn | — | -57.7% | -7,756.4% | −38.2% | +231% / +528% |
| OABIOmniab, Inc. | 755.6 m | — | -16.5% | -108.1% | −29.3% | +250% / +10% |
| NRCNRC Health | 574.5 m | 95.9 | 248.1% | 4.5% | −4.0% | +59% / −35% |
| ONMDOnemednet Corporation | 269.2 m | — | — | -584.2% | +111.4% | −75% / −89% |
| MXCTMaxCyte, Inc. | 143.5 m | — | -20.4% | -114.8% | −14.5% | −21% / −71% |
| BIAFbioAffinity Technologies, Inc. | 23.7 m | — | -1,860.2% | -257.3% | −34.2% | −87% / −100% |
| ISPCiSpecimen Inc. | 2.1 m | — | -968.5% | -2,449.0% | −79.2% | −95% / −100% |
1- and 3-year price returns: for OABI from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 06 Aug 2026; since then the company filed 8-K (30 Oct 2026 · results), 10-Q (30 Oct 2026).
In brief
OmniAb licenses antibody discovery technology to pharmaceutical, biotech and academic customers, earning revenue from access fees, services, milestones and royalties. The company raised its 2026 outlook in August 2026, amid business momentum and 27.8 mn USD of revenue in the first half. For readers, the outcome depends largely on partner programs that OmniAb does not control.
SWOT
Strengths
- The company holds proprietary transgenic animals and the xPloration screening platform, with many active programs across numerous partners 12.
- The licence model with long-term royalties and patents linked to discovered antibodies can diversify revenue streams over time 1.
- The 2026 outlook was raised and the company reported a smaller net loss in the first half 3.
Weaknesses
- Revenue is volatile and depends on the timing of milestones achieved by partners, which the company does not control 1.
- The company has reported net losses over several years and it is uncertain whether it will reach sustained profitability 1.
- Disclosure of program information depends on partners, who may decide when and whether to make it public 1.
Opportunities
- Expanding xPloration and AI tools could attract new partners or increase instrument sales 13.
- If partner programs advance to later clinical phases, milestones and royalties could grow significantly 3.
- Growth in the antibody class could widen the market for discovery technologies, including newer modalities 1.
Risks
- Dependence on partnershigh
The economic value of agreements depends on partner milestones and royalties, which partners control in development and commercialization 1.
- Irregular revenuehigh
Revenue depends on the timing of new licences and milestones, which makes quarterly results hard to forecast 1.
- Persistent net lossesmedium
The company has reported losses over several years and it is uncertain whether it will reach durable profitability 13.
- Intellectual property protectionmedium
If patents do not cover the technology broadly enough, competitors could replicate the company's platforms 1.
- Third-party licencesmedium
Loss of licence rights in a dispute could limit platform development 1.
Investment thesis
What would need to be true (bull case)
- If partner programs advance, milestones and royalties could significantly raise long-term revenue 13.
- The raised 2026 outlook and growth in partners and programs point to adoption of the platform 23.
- The xPloration platform and AI tools could become an additional source of instrument sales revenue 13.
What would break the thesis
- Revenue remains volatile and depends on decisions the company does not control, and a single program failure could undo expectations 1.
- The company has not yet reached profitability, and losses and impairments could continue 13.
- Competition and industry pricing pressure could limit the company's ability to grow revenue 1.
What to watch
- Delivery of the 2026 revenue guidance of 32 to 36 mn USD2026
- Progress of partner programs in Phase 3, including oncology programs2027
- Strategy and technology plans presented at the October Investor and Analyst DayQ4 2026
- Development of active partner and program counts in quarterly reportsQ1 2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 06 Aug 2026; since then the company filed 8-K (30 Oct 2026 · results), 10-Q (30 Oct 2026).
The business
OmniAb, Inc. (NASDAQ: OABI) provides antibody discovery research technology built on its proprietary transgenic animals (OmniRat, OmniChicken, OmniMouse) and the xPloration screening platform 12. Its business model uses license agreements that include access fees, payments for services, development milestones and royalties on partner sales 1. As of December 31, 2025 it had 107 active partners, and total revenue for 2025 was 18.666 mn USD, down from 26.391 mn USD in 2024 1.
In the short term revenue is driven by milestone and service payments, while in the longer term royalties from global sales of partner products are expected to matter more 1. Management stresses that OmniAb does not control the clinical development, regulatory strategy or commercialization of partner programs, making the company dependent on partner decisions 1. Partners can terminate agreements without penalty, but accrued milestones and royalties survive termination 1.
Segments
License and milestone revenue
License and milestone revenue was 9.771 mn USD in 2025, down from 13.866 mn USD in 2024, reflecting the timing of new agreements and partner milestone achievement 1. In the second quarter of 2026 revenue growth was driven mainly by milestones 3.
Service and xPloration revenue
Service revenue fell to 7.263 mn USD in 2025 after completion or discontinuation of certain small-molecule ion channel programs 1. xPloration generated 754 thousand USD of revenue in 2025 following the launch of a partner access program, and in 2026 instrument and consumable sales increased 13.
Market context
Antibodies are among the fastest-growing drug classes and are used in oncology, immunology and neurodegeneration 1. The source cites a BIO study of over 9,000 clinical programs showing higher success rates for antibodies 1. The addressable market for antibody discovery technologies could expand if investment in this class continues 1.
The US Inflation Reduction Act gives an incentive to biologics, which can be subject to Medicare price negotiation 11 years after approval versus 7 years for small molecules 1. The same law also imposes additional burdens on the pharmaceutical industry 1.
Trends
- Rising interest in antibodiestailwind
Favourable properties of antibodies, such as high specificity and less frequent dosing, have accelerated investment and raised success rates in this class 1. If this trend holds, demand for discovery platforms could remain solid 1.
- IRA incentive for biologicsmixed
The Inflation Reduction Act gives biologics a longer period before price negotiation, which could encourage antibody investment 1. At the same time, pricing pressure on the industry could limit partner profits 1.
- Pressure on research costsheadwind
The company reduced research and development and general and administrative expenses in 2025 and the first half of 2026, but recorded impairments on small-molecule assets 13. If cost reductions do not persist, operating margins could remain under pressure 3.
- Partner programs advancing into the clinictailwind
Several partner programs advanced, including a tri-specific antibody that moved into Phase 3 and an ADC in Phase 3 for colorectal cancer 3. Progress of these programs could generate milestones and, over time, royalties for OmniAb 3.
Competitive position
The sources describe the biotech platform technology market as highly competitive, and competition could affect the company's ability to maintain or grow revenue 1. OmniAb differentiates by combining several transgenic species, single-cell screening and AI tools, but the sources do not detail direct competitors 1.
Intellectual property protection is a key factor, because competitors could develop similar technologies if protection is not broad enough 1. The company also relies on licences obtained from third parties, the loss of which could materially affect operations 1.
- Antibody discovery platform providers
Companies offering competing antibody discovery platforms; the sources do not name them, so they are not identified individually.
- Hybridoma discovery methods
The hybridoma method is the industry standard that OmniAb's single B cell analysis is positioned against 1.
- Transgenic mouse platforms
The sources mention several commercially available transgenic mouse options, whereas OmniAb also includes rat, chicken and cow technologies 1.
- Partners developing antibodies internally
Partners that develop programs could compete indirectly through their own internal antibody pipelines 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Is OmniAb (OABI)’s Eli Lilly (LLY) Partnership a Game Changer for OABI?Yahoo Finance — News · 28 Aug 2026 · EN
The latest news item in our archive is from 28 Aug 2026; the newest SEC filing is from 30 Oct 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Quarterly report30 Oct 2026
- Current report30 Oct 2026Results of operations · Financial statements and exhibits
- Quarterly report06 Aug 2026
- Current report06 Aug 2026Results of operations · Financial statements and exhibits
- Current report13 Jul 2026Departure or appointment of officers
- Current report18 Jun 2026Shareholder vote
- Quarterly report07 May 2026
- Current report07 May 2026Results of operations · Financial statements and exhibits
- Proxy statement29 Apr 2026
- Annual report04 Mar 2026
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / OmniAb, Inc. · 04 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / OmniAb, Inc. · 06 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / OmniAb, Inc. · 06 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.